Cargando…
VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice
To address the possible involvement of VGF peptides in obesity and diabetes, we studied type 2 diabetes (T2D) and obese patients, and high-fat diet induced obese mice. Two VGF peptides (NAPP-19 and QQET-30) were identified in human plasma by HPLC-ESI-MS. The VGF C-terminus, the above two cleaved pep...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643017/ https://www.ncbi.nlm.nih.gov/pubmed/26562304 http://dx.doi.org/10.1371/journal.pone.0142333 |
_version_ | 1782400452066803712 |
---|---|
author | D’Amato, Filomena Noli, Barbara Angioni, Laura Cossu, Efisio Incani, Michela Messana, Irene Manconi, Barbara Solinas, Paola Isola, Raffaella Mariotti, Stefano Ferri, Gian-Luca Cocco, Cristina |
author_facet | D’Amato, Filomena Noli, Barbara Angioni, Laura Cossu, Efisio Incani, Michela Messana, Irene Manconi, Barbara Solinas, Paola Isola, Raffaella Mariotti, Stefano Ferri, Gian-Luca Cocco, Cristina |
author_sort | D’Amato, Filomena |
collection | PubMed |
description | To address the possible involvement of VGF peptides in obesity and diabetes, we studied type 2 diabetes (T2D) and obese patients, and high-fat diet induced obese mice. Two VGF peptides (NAPP-19 and QQET-30) were identified in human plasma by HPLC-ESI-MS. The VGF C-terminus, the above two cleaved peptides, and the TLQP-21 related peptide/s were studied using ELISA and immunohistochemistry. In euglycemic patients, plasma NAPPE and TLQP like peptides were significantly reduced with obesity (74±10 vs. 167±28, and 92±10 vs. 191±19 pmol/ml, mean+SEM, n = 10 and 6, obese vs. normal BMI, respectively, p<0.03). Upon a standard glucose load, a distinct response was shown for VGF C-terminus, TLQP and QQET-like (ERVW immunoreactive) peptides in euglycemic normal BMI patients, but was virtually abolished in euglycemic obese, and in T2D patients independently of BMI. High-fat diet induced obese mice showed reduced plasma VGF C-terminus, NAPPE and QQET-like (ERVW) peptide/s (3±0.2 vs. 4.6±0.3, 22±3.5 vs. 34±1.3, and 48±7 vs. 100±7 pmol/ml, mean+SEM, n = 8/group, obese vs. slim, respectively, p<0.03), with a loss of the response to glucose for all VGF peptides studied. In immunohistochemistry, TLQP and/or VGF C-terminus antibodies labelled VGF containing perikarya in mouse celiac ganglia, pancreatic islet cells and thin beaded nerve fibres in brown adipose tissues, with fewer in white adipose tissue. Upon the glucose load, tyrosine hydroxylase and VGF C-terminus immunoreactive axons became apparent in pancreatic islets of slim animals, but not in obese animals. Alltogether, a significant loss of VGF peptide immunoreactivity and/or their response to glucose was demonstrated in obese patients, with or without T2D, in parallel with a similar loss in high-fat diet induced obese mice. An involvement of VGF in metabolic regulations, including those of brown and/or white adipose tissues is underlined, and may point out specific VGF peptides as potential targets for diagnosis and/or treatment. |
format | Online Article Text |
id | pubmed-4643017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-46430172015-11-18 VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice D’Amato, Filomena Noli, Barbara Angioni, Laura Cossu, Efisio Incani, Michela Messana, Irene Manconi, Barbara Solinas, Paola Isola, Raffaella Mariotti, Stefano Ferri, Gian-Luca Cocco, Cristina PLoS One Research Article To address the possible involvement of VGF peptides in obesity and diabetes, we studied type 2 diabetes (T2D) and obese patients, and high-fat diet induced obese mice. Two VGF peptides (NAPP-19 and QQET-30) were identified in human plasma by HPLC-ESI-MS. The VGF C-terminus, the above two cleaved peptides, and the TLQP-21 related peptide/s were studied using ELISA and immunohistochemistry. In euglycemic patients, plasma NAPPE and TLQP like peptides were significantly reduced with obesity (74±10 vs. 167±28, and 92±10 vs. 191±19 pmol/ml, mean+SEM, n = 10 and 6, obese vs. normal BMI, respectively, p<0.03). Upon a standard glucose load, a distinct response was shown for VGF C-terminus, TLQP and QQET-like (ERVW immunoreactive) peptides in euglycemic normal BMI patients, but was virtually abolished in euglycemic obese, and in T2D patients independently of BMI. High-fat diet induced obese mice showed reduced plasma VGF C-terminus, NAPPE and QQET-like (ERVW) peptide/s (3±0.2 vs. 4.6±0.3, 22±3.5 vs. 34±1.3, and 48±7 vs. 100±7 pmol/ml, mean+SEM, n = 8/group, obese vs. slim, respectively, p<0.03), with a loss of the response to glucose for all VGF peptides studied. In immunohistochemistry, TLQP and/or VGF C-terminus antibodies labelled VGF containing perikarya in mouse celiac ganglia, pancreatic islet cells and thin beaded nerve fibres in brown adipose tissues, with fewer in white adipose tissue. Upon the glucose load, tyrosine hydroxylase and VGF C-terminus immunoreactive axons became apparent in pancreatic islets of slim animals, but not in obese animals. Alltogether, a significant loss of VGF peptide immunoreactivity and/or their response to glucose was demonstrated in obese patients, with or without T2D, in parallel with a similar loss in high-fat diet induced obese mice. An involvement of VGF in metabolic regulations, including those of brown and/or white adipose tissues is underlined, and may point out specific VGF peptides as potential targets for diagnosis and/or treatment. Public Library of Science 2015-11-12 /pmc/articles/PMC4643017/ /pubmed/26562304 http://dx.doi.org/10.1371/journal.pone.0142333 Text en © 2015 D’Amato et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article D’Amato, Filomena Noli, Barbara Angioni, Laura Cossu, Efisio Incani, Michela Messana, Irene Manconi, Barbara Solinas, Paola Isola, Raffaella Mariotti, Stefano Ferri, Gian-Luca Cocco, Cristina VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice |
title | VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice |
title_full | VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice |
title_fullStr | VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice |
title_full_unstemmed | VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice |
title_short | VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice |
title_sort | vgf peptide profiles in type 2 diabetic patients’ plasma and in obese mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643017/ https://www.ncbi.nlm.nih.gov/pubmed/26562304 http://dx.doi.org/10.1371/journal.pone.0142333 |
work_keys_str_mv | AT damatofilomena vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT nolibarbara vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT angionilaura vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT cossuefisio vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT incanimichela vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT messanairene vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT manconibarbara vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT solinaspaola vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT isolaraffaella vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT mariottistefano vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT ferrigianluca vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice AT coccocristina vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice |